BVS Bioventus Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1665988 · Fiscal year ends 12/31
Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.9%
TTM net income YoY655.0%
TTM EPS YoY575.0%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—
Margins
Gross margin68.7%
Operating margin9.7%
Net margin9.8%
FCF margin14.5%
EBITDA margin14.0%
Returns
ROE28.2%
ROA8.3%
ROIC (approx.)12.8%
Asset turnover0.85x
Leverage & solvency
Liabilities / assets56.7%
Debt / equity0.96x
Current ratio1.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.53x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $568.09M | $573.28M | $512.35M | $512.12M | $430.90M |
| Cost of revenue | $179.93M | $185.05M | $184.15M | $181.04M | $128.19M |
| Gross profit | $388.16M | $388.23M | $328.19M | $331.08M | $302.71M |
| R&D expense | $12.11M | $13.95M | $13.45M | $23.85M | $19.04M |
| SG&A expense | $314.03M | $343.80M | $303.88M | $332.13M | $254.25M |
| Operating income | $53.98M | -$15.20M | -$81.72M | -$167.23M | $12.06M |
| Pretax income | $25.71M | -$52.34M | -$121.11M | -$189.03M | $9.49M |
| Income tax | -$1.56M | -$5.29M | $85,000 | -$44.37M | -$1.97M |
| Net income | $22.73M | -$36.12M | -$156.23M | -$158.70M | $19.38M |
| EBITDA | $100.99M | $34.36M | -$24.36M | -$111.84M | $46.94M |
| EPS (basic) | 0.34 | -0.56 | -2.49 | -2.59 | -0.15 |
| EPS (diluted) | 0.33 | -0.56 | -2.49 | -2.59 | -0.15 |
| Weighted avg. shares (diluted) | 68.91M | 64.55M | 62.65M | 61.39M | 45.47M |
| Balance sheet | |||||
| Cash & equivalents | $51.24M | $41.58M | $36.96M | $31.84M | $99.21M |
| Receivables | $128.30M | $127.39M | $122.79M | $136.29M | $124.96M |
| Inventory | $82.24M | $92.47M | $91.33M | $84.77M | $61.69M |
| Current assets | $272.84M | $275.61M | $268.00M | $272.57M | $263.10M |
| PP&E, net | $21.90M | $27.01M | $36.60M | $27.46M | $22.98M |
| Goodwill | $7.46M | $7.46M | $7.46M | $7.46M | $147.62M |
| Intangibles | $368.42M | $404.73M | $482.35M | $639.85M | $695.19M |
| Total assets | $683.56M | $727.96M | $810.91M | $1.37B | $1.23B |
| Current liabilities | $160.38M | $210.40M | $175.50M | $304.02M | $180.86M |
| Short-term debt | $15.00M | $27.34M | $27.85M | $33.06M | $18.04M |
| Long-term debt | $278.95M | $308.29M | $367.00M | $385.01M | $339.64M |
| Total debt | $293.95M | $335.63M | $394.85M | $418.07M | $357.68M |
| Total liabilities | $455.11M | $542.35M | $589.79M | $960.43M | $618.21M |
| Shareholders' equity | $184.10M | $147.94M | $173.59M | $325.24M | $458.92M |
| Net debt | $242.71M | $294.05M | $357.88M | $386.23M | $258.47M |
| Cash flow statement | |||||
| Operating cash flow | $74.67M | $38.80M | $15.34M | -$13.54M | $22.99M |
| Capital expenditure | $2.56M | $1.01M | $7.36M | $1.48M | $13.52M |
| Free cash flow | $72.11M | $37.79M | $7.98M | -$15.02M | $9.47M |
| Investing cash flow | -$3.25M | $22.96M | $15.81M | -$116.44M | -$283.76M |
| Financing cash flow | -$62.14M | -$54.58M | -$26.65M | $62.08M | $273.37M |
| Depreciation & amortization | $47.01M | $49.55M | $57.37M | $55.40M | $34.88M |
| Stock-based compensation | $12.67M | $13.27M | $2.72M | $17.59M | $19.84M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.